Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. - Wikidata - awgldk - TriplyDB

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

http://www.wikidata.org/entity/Q39648546

about

Rituximab use in adult primary glomerulopathy: where is the evidence?Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.Altered B cell signalling in autoimmunity.Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.Treatment with rituximab in idiopathic membranous nephropathy.Primary Membranous Nephropathy.Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Membranous nephropathy-one morphologic pattern with different diseases.Treatment of membranous nephropathy: time for a paradigm shift.Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy.CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy.Treatment of primary membranous nephropathy: where are we now?Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.Continuing the paradigm shift in the treatment of idiopathic membranous nephropathy.Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN.Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.Glomerular disease in 2016: New advances in the treatment of glomerular disease.Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy.Growth Differentiation Factor-15 as a Predictor of Idiopathic Membranous Nephropathy Progression: A Retrospective Study.The Role of PLA2R Antibody in Treatment of Membranous Nephropathy.Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.Membranous Nephropathy in a Patient With Common Variable Immune Deficiency.

P2860

Q28075564-756E40D6-5759-49CE-BBD5-38F43354357D Q33885872-12928221-4959-4F42-92C0-6F5076439226 Q33924642-90A50F61-B089-4BED-8DEF-1EAAAF2380EC Q36296621-3DD67320-26DD-42E3-B10D-7CC1F0A59CC0 Q37511019-C27165EC-4105-41E8-A64D-508A9483E82E Q38760741-F4E677D9-C9D9-49DE-A89F-99D2A2E683E7 Q39335899-51182C89-ACC1-4775-9F2A-8289DBFCB975 Q39337229-663D8D61-1888-47E6-AD09-1AA8259B48EB Q39410091-CEF07516-E98D-4D6F-B12B-B3660C913FFD Q41622450-3AFB884E-7EAB-4314-984F-C95227FCAD06 Q43763546-723ECB85-3D25-42A4-B0D9-4AEDDD7D4E8A Q47850601-3F7B8336-A1E1-4589-BEFC-7E988A4B66A3 Q47962363-0C2877C4-AAA4-4ECE-80B4-C9541A878AB7 Q49852959-45B62A3C-3A5D-46DC-A08A-B97C95C7B1BD Q49921840-8F2E8E3B-DF71-4158-9B5E-BF6BA453F0F0 Q50116914-873FB10F-37E5-495E-8684-34E610AF020B Q52603155-842DADFA-86BD-4B25-A958-E720AFC46B52 Q52670774-3DA4E22E-44A7-48E9-B5B2-8675A3E97978 Q52846990-42953D7D-178D-4CAC-9202-91ADDE11EFAE Q53566669-ADCE7FAF-FA2A-4E4E-9BFF-D2979C0A78F8 Q53882185-96AF9F8D-B950-4996-A3A3-DCE112749788 Q55073803-B0926B5B-0EEC-4AF7-9967-5AACA6BAFC11 Q55222782-8EA4F6D6-A5FA-4C26-BBDF-B86C64C82BFC Q55287848-8AF4C4E1-F2E4-4149-A695-BC920A45FC03 Q55378803-D1539D63-5668-4B08-9DB3-15B7B358534D

P2860

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

http://www.wikidata.org/entity/Q39648546

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

@en

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

@nl

type

label

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

@en

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

@nl

prefLabel

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

@en

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

@nl

P1433

Q39648546-6324B314-20CE-4D30-9571-5708C30CC052

P1476

Q39648546-8696CFC5-394E-4D9C-98C3-62A11BF1F2FD

P2093

Q39648546-01F46A0E-9A70-4533-BE20-B2E045E788AF

Q39648546-058E9F77-EEC3-4AB3-9A05-EA414CF3FB61

Q39648546-070D860E-4F48-4F3B-B535-5AACB8002698

Q39648546-181D18D8-2564-4C36-BA97-1E10A7FED474

Q39648546-4400D65A-C3F9-475D-9E33-DA96987B17A4

Q39648546-48547FBB-26D1-46B8-B54B-F60AF430C0F7

Q39648546-527618C9-F2FB-4781-BF97-5EEB4F8A0189

Q39648546-6E31CE39-09D3-4AA3-806C-17132C1544AD

Q39648546-72356440-7753-4D32-8C55-B46D287C02C0

Q39648546-9F1B3B08-0F2C-4826-B99E-1CA691B48F5A

P2860

Q39648546-14DFF2D9-1F61-47C2-8A8C-75F19EBDE73F

Q39648546-261DA89A-2731-4392-9693-A3AD9D02D049

Q39648546-2D590F81-2CDB-4E47-98CF-36319BB62068

Q39648546-39C67783-6BAB-434F-BB01-2D9CE0DDBBB2

Q39648546-4C38437A-842B-4917-87AC-906717E3A640

Q39648546-54503A89-D674-43A1-B8B9-A3ACF788C129

Q39648546-5ABC6B86-C743-4335-AA32-6751470BBD44

Q39648546-5F9D37F0-75DD-4EB6-8B84-5F35CAFC932C

Q39648546-61FF36AE-9764-4367-956B-0A7D37C32998

Q39648546-69FD62FF-C0C2-4D09-9251-419B209D5B61

P304

Q39648546-742E639B-D094-478B-9EC4-2D3B3AB9B894

P31

Q39648546-D9D4D1D4-B05B-4D64-BE0B-032DE9D2D177

P356

Q39648546-784B9BFF-6542-4845-B5F6-63CBB09ADAAE

P433

Q39648546-F5D1D8FD-37DA-4FC1-AD2E-FB9CCD2156CC

P478

Q39648546-74B4E8F7-F02A-46C0-8082-4E3B50E067FE

P50

Q39648546-ED21F881-5E24-4631-8562-CD27C5DDC8EA

P577

Q39648546-388104F7-27F8-4B3C-B3BD-DB2220913EDF

P698

Q39648546-302F3FFD-7D13-428A-8F40-6AABF25C6D96

P932

Q39648546-D551321D-C4E6-4BFC-9058-E18D1AB8D169

P356

P1433

Journal of the American Society of Nephrology

P1476

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

@en

P2093

Alexandra Rousseau

http://www.w3.org/2001/XMLSchema#string

Bertrand Dussol

http://www.w3.org/2001/XMLSchema#string

Christiane Mousson

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Plaisier

http://www.w3.org/2001/XMLSchema#string

Fabrice Mihout

http://www.w3.org/2001/XMLSchema#string

GEMRITUX Study Group

http://www.w3.org/2001/XMLSchema#string

Hanna Debiec

http://www.w3.org/2001/XMLSchema#string

Karine Dahan

http://www.w3.org/2001/XMLSchema#string

Laura Wakselman

http://www.w3.org/2001/XMLSchema#string

Marie Matignon

http://www.w3.org/2001/XMLSchema#string

P2860

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.

A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy

The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy

Rituximab in idiopathic membranous nephropathy.

P304

348-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2016040449

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Tabassome Simon

P577

2016-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27352623

http://www.w3.org/2001/XMLSchema#string

P932

5198292

http://www.w3.org/2001/XMLSchema#string